Resource Center
Eurofins Viracor's TA-TMA (Transplant-associated thrombotic microangiopathy) testing stands out for its comprehensiveness, offering clinicians a complete assessment of complement pathway regulation and potential deregulation with validated assays for Eculizumab, CH50, and sC5b-9...
This bi-lateral lung transplant recipient is a 65 year-old male patient who received his lung transplant due to end-stage lung disease secondary to non-CF bronchiectasis. The donor and recipient CMV serostatus is D+/R+. The patient’s initial peri-operative course was complicated by difficult explant, primary graft dysfunction, respiratory failure requiring prolonged mechanical ventilation, renal insufficiency and recurrent infectious concerns, including pseudomonas and stenotrophomonas pneumonias.